Dosage and administration for preventing cardiotoxicity in treatment with ERbB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents
US9610249B2 · kind B2 · utility
0Cited by
13References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 21, 2015 |
| Grant date | Apr 4, 2017 |
| Priority date | — |
| Expiry date | Aug 21, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/566
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.